Urinary Protein Excretion Increases Risk of Cognitive Decline
By LabMedica International staff writers Posted on 23 Dec 2010 |
A simple urine test could identify individuals at risk from suffering from irrational behavior and confusion.
Albuminuria, a pathological condition where the protein albumin is excreted in the urine, and low kidney function as estimated by the glomerular filtration rate, are indicative of cognitive impairment.
In a study, carried out at Stanford University (Stanford, CA, USA), clinical data from 19,399 individuals was collected to see whether cognitive decline was associated with albuminuria and deficient renal function. A total of 1,184 participants (6.1%) developed cognitive impairment over an average follow-up of 3.8 years. Individuals with albuminuria were 1.31-1.57 times more likely to develop cognitive impairment compared to individuals without albuminuria.
This association was strongest for individuals with normal kidney function who had an estimated glomerular filtration rate (eGFR) equal to or greater than 60 mL/min/1.73 m2, but was attenuated among individuals with low levels of kidney function. Conversely, low kidney function with eGFR of less than 60 mL/min/1.73 m2, was associated with a higher risk for developing cognitive impairment only among individuals without albuminuria. Individuals with albuminuria and normal kidney function had a higher probability for developing cognitive impairment as compared to individuals with moderate reductions in kidney function with eGFR of 45-59 mL/min/1.73 m2, in the absence of albuminuria.
Manjula Kurella Tamura, MD, from Stanford University, said, "The results are important because albuminuria is easily measured and potentially modifiable. Incorporating information about albuminuria along with kidney function should help clinicians identify patients at high risk for subsequent cognitive decline and dementia." The findings indicate that the presence of protein in the urine, even in small amounts, could be a warning sign that a patient may later have difficulty thinking clearly. The study was presented orally at the annual meeting of American Society of Nephrology, held in Denver, CO, USA, November 16 – 21, 2010.
Related Links:
Stanford University
Albuminuria, a pathological condition where the protein albumin is excreted in the urine, and low kidney function as estimated by the glomerular filtration rate, are indicative of cognitive impairment.
In a study, carried out at Stanford University (Stanford, CA, USA), clinical data from 19,399 individuals was collected to see whether cognitive decline was associated with albuminuria and deficient renal function. A total of 1,184 participants (6.1%) developed cognitive impairment over an average follow-up of 3.8 years. Individuals with albuminuria were 1.31-1.57 times more likely to develop cognitive impairment compared to individuals without albuminuria.
This association was strongest for individuals with normal kidney function who had an estimated glomerular filtration rate (eGFR) equal to or greater than 60 mL/min/1.73 m2, but was attenuated among individuals with low levels of kidney function. Conversely, low kidney function with eGFR of less than 60 mL/min/1.73 m2, was associated with a higher risk for developing cognitive impairment only among individuals without albuminuria. Individuals with albuminuria and normal kidney function had a higher probability for developing cognitive impairment as compared to individuals with moderate reductions in kidney function with eGFR of 45-59 mL/min/1.73 m2, in the absence of albuminuria.
Manjula Kurella Tamura, MD, from Stanford University, said, "The results are important because albuminuria is easily measured and potentially modifiable. Incorporating information about albuminuria along with kidney function should help clinicians identify patients at high risk for subsequent cognitive decline and dementia." The findings indicate that the presence of protein in the urine, even in small amounts, could be a warning sign that a patient may later have difficulty thinking clearly. The study was presented orally at the annual meeting of American Society of Nephrology, held in Denver, CO, USA, November 16 – 21, 2010.
Related Links:
Stanford University
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines